Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 6/20 | 0.48 |
| ▸ | CES1 | P23141 | 4/20 | 0.48 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL9143198 | 1.00 | ALDH1A1 (0.62) | ALDH1A1EPHX1FAAHCES2CES1 | |
| Hexane SCHEMBL3254219 | 1.00 | ALDH1A1 (0.62) | ALDH1A1EPHX1FAAHCES2CES1 | |
| Hexane SCHEMBL3428301 | 1.00 | ALDH1A1 (0.62) | ALDH1A1EPHX1FAAHCES2CES1 | |
| Hexane SCHEMBL1273659 | 1.00 | ALDH1A1 (0.62) | ALDH1A1EPHX1FAAHCES2CES1 | |
| Hexane SCHEMBL5781814 | 1.00 | ALDH1A1 (0.62) | ALDH1A1EPHX1FAAHCES2CES1 | |
| Hexane SCHEMBL28216413 | 0.97 | ALDH1A1 (0.59) | ALDH1A1EPHX1FAAHCES2CES1 | |
| Pentadecane SCHEMBL30878097 | 0.97 | ALDH1A1 (0.59) | ALDH1A1EPHX1FAAHCES2CES1 | |
| Heptane SCHEMBL8984142 | 0.97 | ALDH1A1 (0.59) | ALDH1A1EPHX1FAAHCES2CES1 | |
| Decane SCHEMBL27650522 | 0.97 | ALDH1A1 (0.59) | ALDH1A1EPHX1FAAHCES2CES1 | |
| Octane SCHEMBL28055318 | 0.97 | ALDH1A1 (0.59) | ALDH1A1EPHX1FAAHCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117046514-A | Catalyst for liquid-phase Beckmann rearrangement as well as preparation method and application thereof | 北京旭阳科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-115466346-B | Preparation method of polymer thickener in polar solvent | 中国天辰工程有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117046514-A | Catalyst for liquid-phase Beckmann rearrangement as well as preparation method and application thereof | 北京旭阳科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230183276-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-15 | — | — | US | disclosed |
| CN-115466346-A | Preparation method of polymer thickener in polar solvent | 中国天辰工程有限公司 | 2022-12-13 | — | — | CN | disclosed |
| EP-3943489-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | Vertex Pharmaceuticals Incorporated (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3608315-B1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | VERTEX PHARMA (US) | 2021-08-11 | — | — | EP | disclosed |
| US-RE48266-E1 | Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-10-20 | — | — | US | disclosed |
| EP-3608315-A1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Vertex Pharmaceuticals Incorporated (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3305776-B1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | VERTEX PHARMA (US) | 2019-09-25 | — | — | EP | disclosed |
| US-4465689-A | MONIC ACID ESTERS | BEECHAM GROUP LIMITED (GB) | 1984-08-14 | — | — | US | disclosed |
| EP-0049049-A1 | 5-Amino-tetrazole derivatives, processes for their preparation and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1982-04-07 | — | — | EP | disclosed |
| US-4318856-A | Antibacterial compounds | BEECHAM GROUP LIMITED (GB) | 1982-03-09 | — | — | US | disclosed |
| US-4289779-A | HETEROCYCLIC ESTERS OF MONIC ACID; TREATMENT OF PENICILLIN-RESISTANT GONORRHEA | BEECHAM GROUP LIMITED (GB) | 1981-09-15 | — | — | US | disclosed |
| US-4283412-A | MONIC ACID | BEECHAM GROUP LIMITED (GB) | 1981-08-11 | — | — | US | disclosed |
| US-4283411-A | MONIC ACID | BEECHAM GROUP LIMITED (GB) | 1981-08-11 | — | — | US | disclosed |
| US-4267316-A | HETEROCYCLIC ESTERS OF PSEUDOMONIC ACID; UROGENITAL DISORDERS; NEISSERIA; BRONCHIUS; VETERINARY MEDICINE | BEECHAM GROUP LIMITED (GB) | 1981-05-12 | — | — | US | disclosed |
| US-4217448-A | MONIC ACID DERIVATIVES | BEECHAM GROUP LIMITED (GB) | 1980-08-12 | — | — | US | disclosed |
| US-4166863-A | ACTIVE AGAINST HEMOPHILUS AND NEISSERIA | BEECHAM GROUP LIMITED (GB) | 1979-09-04 | — | — | US | disclosed |
| US-4163758-A | 2-Nitroethylcyclopentane compounds and process for preparing the same | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1979-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183276-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | MAPK1, MAP3K1, MAP3K20 | ALDH1A1 2808/4885EPHX1 977/4885FAAH 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.